Related Experiment Videos
Platelet 3H-imipramine binding during recovery from depression
P M Ellis1, R Beeston, C J McIntosh
1Department of Psychological Medicine, Wellington School of Medicine, University of Otago, New Zealand.
Acta Psychiatrica Scandinavica
|August 1, 1992
Summary
Decreased platelet imipramine binding (Bmax) may indicate depression. This study found lower initial Bmax in depressed patients but no clear link between Bmax changes and depression recovery over six months.
Area of Science:
- Neuroscience
- Psychiatry
- Biochemistry
Background:
- Decreased binding of tritiated imipramine to platelets has been proposed as a potential biological marker for depression.
- The dynamic changes in imipramine binding parameters during the course of depression treatment and recovery remain unclear.
Purpose of the Study:
- To investigate alterations in imipramine binding parameters and depressive symptoms over time in patients with major depression.
- To explore the relationship between changes in imipramine binding and clinical recovery from depression.
Main Methods:
- Studied 25 patients diagnosed with major depression.
- Assessed imipramine binding parameters (specifically Bmax) and depressive symptoms at baseline, and at 1, 3, and 6 months post-treatment initiation.
- Compared findings to healthy subjects.
Main Results:
- Depressed patients exhibited significantly lower initial Bmax values compared to healthy controls.
- No clear correlation was established between the recovery from depressive symptoms and the Bmax values over the 6-month study period.
- The study possessed 78% power to detect at least a 10% variance in Bmax related to depression recovery.
Conclusions:
- While reduced imipramine binding may be characteristic of depression, it does not appear to be a reliable indicator of treatment response or recovery.
- Further research is needed to elucidate the role of imipramine binding in the pathophysiology and treatment of major depression.